Biogen beats estimates on cost cuts and new drugs like Leqembi, but profit outlook falls short
Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis products.
You are not logged in so some information on this page has been withheld. To see more, please log in.
Biogen
since
auto-detected in 3 stories
3 months ago
page 1 of 1